Development of new interventions and treatment for schistosomiasis morbidity control

开发新的干预措施和治疗方法来控制血吸虫病发病率

• 批准号: FT0991222
• 负责人: Dr Yuesheng Li
• 金额: $ 48.96万
• 依托单位: Queensland Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: ARC Future Fellowships
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/FT0991222
• 关键词: Development; new; interventions; treatment; schistosomiasis

Australia has played a lead role in Parasitology research. It is vital to remain at the forefront in combating the human and livestock diseases that parasites cause. Vaccine assessment and the large scale analysis of patient tissues are vital to the biotechnology, agriculture and pharmaceutical industries with outcomes leading to innovative strategies for control. Politically there is value as it is altruistic to develop new tools, technologies and treatments for the Asia/Pacific region. Economically, Australia will have first pass at developing the intellectual property arising. As well, the therapies would be developed locally to the benefit of Australia's human therapeutics industry and bio-reagent manufacturers.

澳大利亚在寄生虫学研究方面发挥了主导作用。至关重要的是，在抗击寄生虫引起的人畜疾病方面保持领先地位。疫苗评估和对患者组织的大规模分析对生物技术、农业和制药行业至关重要，其结果导致创新的控制战略。在政治上是有价值的，因为为亚太地区开发新的工具、技术和治疗方法是无私的。在经济上，澳大利亚将首先通过发展产生的知识产权。此外，这些疗法将在当地开发，以造福于澳大利亚的人体疗法行业和生物试剂制造商。